Physician profile
David R Baker
NPI 1093779316
$4,261.46
in general payments reported to CMS, 2019-2025
33 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $167 · 2021: $135 · 2022: $1,813 · 2023: $573 · 2024: $439 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer International LLC | $1,387.39 | 2022 | |
| Lilly USA, LLC | $517.10 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $455.63 | 2022-2025 | Vraylar, Linzess, Ubrelvy |
| Novo Nordisk INC | $291.70 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $239.94 | 2019-2025 | |
| Pfizer INC. | $194.68 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.19 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $141.06 | 2019-2025 | Trelegy Ellipta |
| Leica Microsystems INC. | $91.16 | 2025 | |
| Abbott Laboratories | $83.41 | 2022-2025 | Proclaim |
| Astrazeneca Pharmaceuticals LP | $79.62 | 2019-2025 | Bevespi Aerosphere |
| Bayer Healthcare Pharmaceuticals INC. | $72.62 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $49.53 | 2020-2022 | |
| Astellas Pharma US INC | $45.53 | 2019-2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $44.87 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.21 | 2021-2024 | Trulance, Xifaxan |
| Sanofi-Aventis U.S. LLC | $37.87 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.21 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.16 | 2022 | |
| Phathom Pharmaceuticals, INC. | $30.80 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $30.42 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $29.14 | 2019 | |
| Dexcom, INC. | $21.65 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $21.61 | 2019 | |
| Avanir Pharmaceuticals, INC. | $21.03 | 2019 | |
| Organogenesis INC. | $18.30 | 2024 | |
| Sanofi Pasteur INC. | $17.84 | 2019 | |
| Grifols USA, LLC | $16.77 | 2020 | |
| Grt US Holding, INC. | $16.58 | 2022 | |
| Vyne Pharmaceuticals INC. | $15.61 | 2020 | |
| Amgen INC. | $14.24 | 2025 | Otezla, Repatha |
| Amarin Pharma, INC. | $11.82 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.